CzeekV インデックス 活用事例・実践,研究報告など、お役立ち情報をシェアします

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database.

• アブストラクト	A better understanding of immune-related adverse events is essential for the early detection and appropriate management of these phenomena. We conducted an observational study of cases recorded at the French reference center for hypereosinophilic syndromes and in the French national pharmacovigilance database. Thirty-seven reports of eosinophilia induced by treatment with immune checkpoint inhibitors (ICIs) were included. The median [range] time to the absolute eosinophil count (AEC) peak was 15 [4 horizontal line 139] weeks. The median AEC was 2.7 [0.8 horizontal line 90.9] G/L. Eosinophil-related manifestations were reported in 21 of the 37 cases (57%). If administered, corticosteroids were always effective (n = 10 out of 10). Partial or complete remission of eosinophilia was obtained in some patients not treated with corticosteroids, after discontinuation (n = 12) or with continuation (n = 4) of the ICI. The AEC should be monitored in ICI-treated patients. If required by oncologic indications, continuation of ICI may be an option in asymptomatic hypereosinophilic patients, and in corticosteroid responders.
  ジャーナル名	Oncoimmunology
  投稿日	2020/4/22
  投稿者	Scanvion, Quentin; Bene, Johana; Gautier, Sophie; Grandvuillemin, Aurelie; Le Beller, Christine; Chenaf, Chouki; Etienne, Nicolas; Brousseau, Solenn; Cortot, Alexis B; Mortier, Laurent; Staumont-Salle, Delphine; Morschhauser, Franck; Forestier, Alexandra; Groh, Matthieu; Launay, David; Hachulla, Eric; Labalette, Myriam; Kahn, Jean-Emmanuel; Lefevre, Guillaume
  組織名	Univ. Lille, CHU Lille, Service de Medecine Interne Et Immunologie Clinique,;Centre de Reference des Maladies Auto-immunes Systemiques Rares du Nord et;Nord-Ouest de France (Ceraino), Lille, France.;Univ. Lille, CHU Lille, Centre Regional de PharmacoVigilance, Lille, France.;CHU Dijon, Service Vigilances-Qualite-Risques, Centre Regional de;PharmacoVigilance, Dijon, France.;Hopital Europeen Georges Pompidou, Centre Regional de PharmacoVigilance,;Assistance Publique-Hopitaux de Paris, Paris, France.;CHU Clermont-Ferrand, Centre Regional de PharmacoVigilance, Clermont-Ferrand,;France.;Centre de Reference National des Syndromes Hypereosinophiliques (CEREO), France.;Hopital Bichat, Service d'Oncologie Thoracique, Assistance Publique-Hopitaux de;Paris, Paris, France.;Univ. Lille, UMR8161, CHU Lille, Service d'Oncologie Thoracique, Lille, France.;Univ. Lille, Inserm U1189, CHU Lille, Service de Dermatologie, Lille, France.;CHU Lille, Service des Maladies du Sang, Lille, France.;Centre Oscar Lambret, Service d'Oncologie, Lille, France.;Hopital Foch, Service de Medecine Interne, Assistance Publique-Hopitaux de Paris,;Suresnes, France.;Univ. Lille, CHU Lille, Institut d'Immunologie, Lille, France.;Hopital Ambroise Pare, Service de Medecine Interne, Assistance Publique-Hopitaux;de Paris, Boulogne Billancourt, France.
  Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/32313716/

  タグ:

  • FPVD

• お問合わせ

  お問合わせ

  検索

  サイト内検索・論文検索

  

  検索

  サイト内 論文

  キーワード

  PubmedID
  Abstract
  Title
  Journal
  Date(投稿日)	～
  Author
  タクソノミー検索	タクソノミー検索 CAERS CARD CPRD CVAR CVARD DeSC DPC EHR ESP-VAERS EudraVigilance FAERS Fibroblasts FPVD GPRD Ionizing JADER JMDC KAERS KIDS-KAERS KIDS-KD MDV NDB Nickel Pharmacoepidemiology Radiation RWE THIN Unknown VAERS VigiBase インフォメーション スコア値 スコア指標 総合ランキング 閾値

  

  メルマガ登録

  購読申し込み